anti-CD3 bispecific T-cell engager (Loxo/Merus)

N/A

Report date: 2026/03/19 16:53:26

Base Information

Drug Nameanti-CD3 bispecific T-cell engager (Loxo/Merus)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsT cell surface glycoprotein CD3 modulators

TargetsT cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesNetherlands

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMerus Nv

China Registration ClassN/A

Develop Information

Active CompaniesMerus Nv +[2]

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A